- Home
- MLYS vs NVGS Comparison
MLYS vs NVGS Comparison
Compare MLYS & NVGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- NVGS
- Stock Information
- Founded
- MLYS 2019
- NVGS 1997
- Country
- MLYS United States
- NVGS United Kingdom
- Employees
- MLYS N/A
- NVGS N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- NVGS Marine Transportation
- Sector
- MLYS Health Care
- NVGS Consumer Discretionary
- Exchange
- MLYS Nasdaq
- NVGS Nasdaq
- Market Cap
- MLYS 1.0B
- NVGS 986.7M
- IPO Year
- MLYS 2023
- NVGS N/A
- Fundamental
- Price
- MLYS $13.48
- NVGS $14.66
- Analyst Decision
- MLYS Strong Buy
- NVGS Strong Buy
- Analyst Count
- MLYS 4
- NVGS 3
- Target Price
- MLYS $27.00
- NVGS $22.00
- AVG Volume (30 Days)
- MLYS 667.1K
- NVGS 388.2K
- Earning Date
- MLYS 08-12-2025
- NVGS 08-13-2025
- Dividend Yield
- MLYS N/A
- NVGS 1.37%
- EPS Growth
- MLYS N/A
- NVGS 9.28
- EPS
- MLYS N/A
- NVGS 1.27
- Revenue
- MLYS N/A
- NVGS $583,931,000.00
- Revenue This Year
- MLYS N/A
- NVGS $3.45
- Revenue Next Year
- MLYS N/A
- NVGS N/A
- P/E Ratio
- MLYS N/A
- NVGS $11.49
- Revenue Growth
- MLYS N/A
- NVGS 6.38
- 52 Week Low
- MLYS $8.24
- NVGS $10.55
- 52 Week High
- MLYS $18.38
- NVGS $18.18
- Technical
- Relative Strength Index (RSI)
- MLYS 35.32
- NVGS 62.35
- Support Level
- MLYS $12.98
- NVGS $14.30
- Resistance Level
- MLYS $16.67
- NVGS $14.90
- Average True Range (ATR)
- MLYS 0.81
- NVGS 0.37
- MACD
- MLYS -0.33
- NVGS 0.02
- Stochastic Oscillator
- MLYS 13.56
- NVGS 80.65
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). Company play a vital role in theglobalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users and commodity traders.